News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
282,181 Results
Type
Article (14915)
Company Profile (299)
Press Release (266961)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (80000)
Career Advice (162)
Deals (13374)
Drug Delivery (39)
Drug Development (50787)
Employer Resources (31)
FDA (5844)
Job Trends (5173)
News (145366)
Policy (10097)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (925)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21800)
ALS (124)
Alzheimer's disease (1032)
Antibody-drug conjugate (ADC) (242)
Approvals (6038)
Artificial intelligence (258)
Autoimmune disease (110)
Automation (9)
Bankruptcy (105)
Best Places to Work (4565)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (343)
Cancer (3128)
Cardiovascular disease (238)
Career advice (147)
Career pathing (7)
CAR-T (217)
CDC (5)
Cell therapy (565)
Cervical cancer (14)
Clinical research (43742)
Collaboration (1151)
Company closure (2)
Compensation (591)
Complete response letters (39)
COVID-19 (1107)
CRISPR (86)
C-suite (551)
Cystic fibrosis (112)
Data (4319)
Denatured (15)
Depression (92)
Diabetes (254)
Diagnostics (1384)
Digital health (11)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (187)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (213)
Earnings (31706)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51789)
Executive appointments (621)
FDA (7593)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (984)
Gene editing (182)
Generative AI (21)
Gene therapy (486)
GLP-1 (505)
Government (1151)
Grass and pollen (3)
Guidances (166)
Healthcare (6628)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1211)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7366)
IRA (12)
Job creations (868)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1407)
Liver cancer (41)
Longevity (11)
Lung cancer (419)
Lymphoma (248)
Machine learning (24)
Management (7)
Manufacturing (376)
MASH (130)
Medical device (2671)
Medtech (2680)
Mergers & acquisitions (6634)
Metabolic disorders (725)
Multiple sclerosis (102)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1952)
Neurotech (1)
NextGen: Class of 2026 (2045)
Non-profit (867)
Now hiring (30)
Obesity (330)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (304)
Patient recruitment (327)
Peanut (43)
People (26688)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15489)
Phase 2 (20327)
Phase 3 (12845)
Pipeline (3239)
Policy (90)
Postmarket research (855)
Preclinical (6536)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (239)
Rare diseases (647)
Real estate (1452)
Recruiting (12)
Regulatory (9908)
Reports (19)
Research institute (974)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (183)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (16)
Startups (2014)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (333)
Venture capital (69)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Last 7 days (344)
Last 30 days (1208)
Last 365 days (17812)
2026 (1654)
2025 (18114)
2024 (20555)
2023 (22438)
2022 (26939)
2021 (27892)
2020 (23430)
2019 (16269)
2018 (11767)
2017 (13756)
2016 (11858)
2015 (14373)
2014 (10424)
2013 (7502)
2012 (7543)
2011 (7648)
2010 (7444)
Location
Africa (155)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18333)
Australia (3111)
California (7084)
Canada (1837)
China (772)
Colorado (246)
Connecticut (252)
Delaware (235)
Europe (39295)
Florida (903)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (396)
India (35)
Indiana (160)
Iowa (8)
Japan (225)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5578)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1645)
New Mexico (13)
New York (1761)
North Carolina (825)
North Dakota (6)
Northern California (3479)
Ohio (178)
Oklahoma (11)
Oregon (24)
Pennsylvania (1278)
Puerto Rico (9)
Rhode Island (25)
South America (231)
South Carolina (9)
Southern California (2812)
Tennessee (40)
Texas (904)
United States (23335)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
282,181 Results for "mina therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
MiNA Therapeutics Presents New Pre-Clinical Data from Sickle Cell Disease Program at the European Hematology Association 2025 Congress
June 12, 2025
·
3 min read
Business
MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases
MiNA Therapeutics today announced a research collaboration and licensing agreement option with Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters: Kyoto; President: Toru Nakai), an innovation-driven Japanese-based pharmaceutical company focused on disease areas of high unmet medical need.
April 4, 2024
·
3 min read
Press Releases
MiNA Therapeutics Appoints Norbert Bischofberger, Ph.D., to its Board as Non-Executive Director and Bríd Ryan, Ph.D., MPH, as Chief Scientific Officer
March 20, 2025
·
2 min read
Business
NS Pharma Announces Research Alliance with MiNA Therapeutics to Develop Therapies for Rare Diseases of the Central Nervous System
NS Pharma, Inc. (NS Pharma) announced that its parent company, Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) – headquartered in Kyoto, Japan, entered into a joint research agreement with MiNA Therapeutics – headquartered in London, United Kingdom, to develop nucleic acid drugs for the potential treatment of intractable and rare diseases of the central nervous system.
April 4, 2024
·
2 min read
MiNA Therapeutics Presents New Data for its HbF Program at the Keystone Symposia’s Delivery of Nucleic Acid Therapeutics Conference
MiNA Therapeutics Limited announced today that it will present new pre-clinical data for its lead RNA activation program targeting fetal hemoglobin (HbF) at the Keystone Symposia’s Delivery of Nucleic Acid Therapeutics Conference in Banff, Alberta, Canada.
January 24, 2024
·
3 min read
Drug Development
MiNA Therapeutics Highlights Preclinical Research on RNA Activation (RNAa) Therapeutics Presented at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting
MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, highlights preclinical research presented by academic partners at the annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.
October 25, 2023
·
2 min read
Press Releases
MiNA Therapeutics Presents New Pre-Clinical Data from Lead Sickle Cell Disease Program at the American Society of Hematology Annual Meeting
December 9, 2024
·
3 min read
Press Releases
Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.
February 7, 2025
·
10 min read
Business
MiNA Therapeutics Enters Research Collaboration with BioMarin Pharmaceutical to Advance RNAa Platform Research in Rare Genetic Diseases
MiNA Therapeutics today announced a multi-target research collaboration and option licensing agreement with BioMarin Pharmaceutical Inc.
April 25, 2023
·
3 min read
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
1 of 28,219
Next
